Selective Insulin and Leptin Resistance in Metabolic Disorders  by Könner, A. Christine & Brüning, Jens C.
Cell Metabolism
PerspectiveSelective Insulin and Leptin
Resistance in Metabolic DisordersA. Christine Ko¨nner1,2,3 and Jens C. Bru¨ning1,2,3,*
1Department of Mouse Genetics and Metabolism, Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging
Associated Diseases (CECAD), Center of Molecular Medicine Cologne (CMMC), University of Cologne, D-50674 Cologne, Germany
2Max Planck Institute for Neurological Research, D-50931 Cologne, Germany
3Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, D-50924 Cologne, Germany
*Correspondence: bruening@nf.mpg.de
http://dx.doi.org/10.1016/j.cmet.2012.07.004
Obesity represents a major risk factor for the development of insulin and leptin resistance, ultimately leading
to a pleiotropic spectrum of metabolic alterations. However, resistance to both hormones does not uniformly
affect all target cells and intracellular signaling pathways. In contrast, numerous clinical phenotypes arise
from selective hormone resistance, leading to inhibition of defined intracellular signaling pathways in
some tissues, while in other cell types hormone action is maintained or even overactivated. Here, we review
themolecular mechanisms and clinical outcomes resulting from selective insulin and leptin resistance, which
should ultimately guide future strategies for the treatment of obesity-associated diseases.Introduction
According to the World Health Organization, more than 1 billion
adults are overweight globally, and at least 300 million of them
are obese (WHO, 2006). Obesity is frequently associated with
insulin resistance, a term that generally describes the inability
of the peptide hormone insulin to maintain glucose homeostasis.
Insulin resistance has also been linked to numerous clinical
conditions such as hypertension, dyslipidemia, atherosclerosis,
cardiovascular disease, polycystic ovaries syndrome, and can-
cer (Mokdad et al., 2003). Moreover, obesity is not only charac-
terized by resistance to the biological effects of insulin but also to
those of the adipocyte-derived hormone leptin (Biddinger and
Kahn, 2006; Myers et al., 2010).
Extensive research over the last several decades provided
important advances in our understanding of the molecular
basis of hormone action and the mechanisms responsible for
the development of insulin and leptin resistance (Hotamisligil,
2006; Konner and Bruning, 2011; Lumeng and Saltiel, 2011).
Importantly, hormone resistance does not develop uniformly
throughout the organism but can affect specific downstream
pathways within a cell or occur in specific cell types and organs,
whereas sensitivity is still maintained in others. Here, we discuss
the pathophysiological consequences of this largely neglected
concept of pathway- and cell type-specific hormonal resistance
both in peripheral tissues and the central nervous system (CNS)
with respect to the manifestation of metabolic disorders.
Insulin Signaling Cascade
Insulin is secreted in response to an increase in glucose concen-
tration and reduces glucose levels by suppressing hepatic
gluconeogenesis and promoting glucose uptake in skeletal
muscle and fat (Taniguchi et al., 2006; White, 2003). Moreover,
insulin regulates glycogenesis, lipogenesis, and protein syn-
thesis (Kahn, 1994). Insulin signaling is triggered by binding
of insulin to the insulin receptor (IR). This activates its intrinsic
tyrosine kinase activity, resulting in tyrosine phosphorylation of
insulin receptor substrate (IRS) proteins (Figure 1). These act144 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.as docking platforms for proteins that contain src homology
region 2 (SH2) domains, such as the p85 regulatory subunit of
the phosphatidylinositol-3 kinase (PI3 kinase). Activation of the
PI3 kinase pathway promotes AKT activation to elicit several
cellular events such as stimulation of glycogen synthesis, inhibi-
tion of gluconeogenesis, and stimulation of glucose uptake (Bid-
dinger and Kahn, 2006; White, 2003) (Figure 1). Insulin’s effects
on lipogenesis are predominantly mediated by the transcription
factor sterol regulatory element-binding protein (SREBP)-1c
that controls the expression of genes required for cholesterol,
fatty acid, triglyceride, and phospholipid synthesis (Ferre and
Foufelle, 2007) (Figure 1).
Another major pathway activated by insulin is the mitogen-
activated protein (MAP) kinase pathway (Biddinger and Kahn,
2006; Kahn, 1994). Insulin-stimulated tyrosine phosphorylation
of the IRS proteins Gab1 and Shc allows for binding of the
adaptor molecule Grb2, which elicits activation of the MAP
kinase cascade via Ras-Raf-ERK1/2 (Figure 1). MAP kinases
can phosphorylate transcription factors such as Elk-1 and are
associated in particular with the proliferative effects of insulin.
Insulin and Leptin Action in the CNS
In addition to its multiple functions in peripheral organs, insulin
also acts on diverse neuronal circuits in the CNS, which are in
control of body weight and metabolism (Belgardt and Bruning,
2010; Plum et al., 2006a). Accordingly, mice with brain-specific
deletion of the IR develop mild obesity and impaired fertility
(Bruning et al., 2000). Maybe even more importantly, insulin
signaling in the CNS is also required for control of peripheral
fat and glucose metabolism (Koch et al., 2008; Konner et al.,
2007; Obici et al., 2002b; Scherer et al., 2011).
The identification of leptin as the product of the obese gene
has defined the proteotypic feedback signal to communicate
fuel availability to the CNS to adapt energy homeostasis (Zhang
et al., 1994). Leptin is released into the circulation in proportion
to the body fat content (Frederich et al., 1995; Maffei et al.,
1995) to inhibit food intake and to stimulate energy expenditure
Figure 1. Molecular Basis of Insulin Action
and Exemplary Mechanisms of Selective
Insulin Resistance
Pure insulin resistance associated with ablation
of the insulin receptor is only seen in rare, genetic
states of insulin resistance such as the type A
syndrome of insulin resistance. Most cases of
insulin resistance result from mutations or poly-
morphisms in downstream signaling molecules or
posttranslational modifications. The Gly972-Arg
polymorphism in IRS-1 impairs insulin-stimulated
signaling, especially along the PI3 kinase pathway.
Moreover, under pathophysiological conditions,
uncontrolled inhibitory IRS serine phosphorylation
by kinases such as JNK and p70 S6 kinase
(S6K) attenuates insulin signaling. Also, a muta-
tion in the gene encoding AKT2 (R274H) contrib-
utes to severe insulin resistance and diabetes
mellitus. In human obesity, insulin stimulation
of muscle glucose uptake via the PI3 kinase
pathway is dramatically reduced, while stimulation
of the MAP kinase pathway is normal. In liver,
selective insulin resistance in the FOXO1 pathway
but preserved signaling through the SREBP-1c
pathway contributes to hyperglycemia and hy-
pertriglyceridemia in type 2 diabetes mellitus. In
addition, altered posttranscriptional gene silenc-
ing via dysregulated miRNA expression can affect
insulin signaling. MicroRNAs 103 and 107 are negative regulators of insulin sensitivity in liver and adipose tissue by targeting calveolin-1, a critical regulator of the
insulin receptor. Moreover, the pancreas-specific microRNA-375 directly targets PDK1 and thereby regulates the glucose-stimulatory action on insulin gene
expression and DNA synthesis. Finally, obesity-induced overexpression of hepatic microRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose
metabolism in an oxysterol-binding protein-related protein (ORP)8-dependent mechanism.
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exerts multiple autonomic and cardiovascular effects, including
activating sympathetic nerve activity, increasing endothelium-
derived nitric oxide, and promoting angiogenesis (Mark et al.,
2002).
The leptin receptor, a cytokine receptor, consists of a single
membrane-spanning domain. Hormone binding to the receptor
triggers the recruitment of the tyrosine kinase Janus kinase
(JAK) 2, leading to the activation of the JAK/STAT (signal trans-
ducer and activator of transcription) signaling pathway on one
hand, and activation of PI3 kinase signaling on the other (Nis-
wender et al., 2001; Vaisse et al., 1996) (Figure 2). Activation of
both pathways has been shown to be required for proper regu-
lation of energy and glucose homeostasis (Bates et al., 2003;
Belgardt et al., 2008; Gao et al., 2004; Hill et al., 2008; Niswender
et al., 2001) (Figure 2).
The Neurocircuitry of Energy Homeostasis
In contrast to the majority of peripheral organs, which are com-
posed of relatively homogenous cell types, a prominent unique
characteristic of the CNS is the existence of thousands of
specialized neuronal subpopulations, which interact in dynamic
functional networks to elicit a coordinated behavioral response.
Also calorie intake, energy expenditure, and peripheral glucose
and fat metabolism are under the tight control of defined
neuronal circuits in the CNS that are targeted by insulin and lep-
tin (Belgardt and Bruning, 2010; Gautron and Elmquist, 2011).
Of particular importance in the control of energy homeostasis
is the melanocortin system, which consists of two functionally
opposing neuronal populations, which are located in the ar-
cuate nucleus (ARC) of the hypothalamus: the anorexigenic,
pro-opiomelanocortin (POMC)-expressing and the orexigenic,
agouti-related peptide/neuropeptide Y (AgRP/NPY)-expressingneurons (Figure 3). POMC-expressing neurons release the
POMC cleavage product a-melanocyte-stimulating hormone
(a-MSH), which acts on melanocortin 4 receptors (MC4R) on
downstream target neurons to reduce food intake, increase
energy expenditure, and regulate glucose metabolism (Cone,
2006; Morton et al., 2006; Xu et al., 2011). In contrast, activation
of AgRP/NPY neurons induces feeding and reduces energy
expenditure (Aponte et al., 2011; Gropp et al., 2005; Krashes
et al., 2011; Luquet et al., 2005). AgRP acts as an inverse agonist
on MC4R, and AgRP/NPY neurons also directly inhibit POMC
neurons through GABA projections (Cowley et al., 2001; Tong
et al., 2008). Both insulin and leptin receptors are expressed
on POMC aswell as AgRP/NPY neurons but also in other regions
of the CNS, which exert critical functions in control of different
aspects of energy and glucose homeostasis, such as the para-
ventricular hypothalamic nucleus (PVN), the ventromedial hypo-
thalamus (VMH), the dorsomedial hypothalamus (DMH), the
lateral hypothalamus (LH), and also in brain structures in control
of reward-related behavior, such as the dopaminergic midbrain
circuitry (Belgardt and Bruning, 2010; Gao and Horvath, 2007;
Klockener et al., 2011; Konner et al., 2011).
Insulin and Leptin Resistance
Resistance to the effects of insulin represents a key process in
the development of type 2 diabetes mellitus (T2DM) (Bruning
et al., 1997; Kahn, 1994). At first, in the prediabetic state,
the b cells of the pancreas increase insulin secretion to compen-
sate for insulin resistance and to maintain a normal glucose
homeostasis (compensatory hyperinsulinemia). However, upon
exhaustion of pancreatic b cells, glucose homeostasis is im-
paired, and overt T2DM develops (Muoio and Newgard, 2008).
The concept of the Insulin Resistance Syndrome aims to
describe the abnormalities and clinical syndromes most likelyCell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc. 145
Figure 2. Convergence of Insulin and Leptin
Signaling
Binding of leptin to the long form of the leptin
receptor (ObRb) leads to activation of Janus
kinase (JAK) 2 and, subsequently, to JAK2-medi-
ated phosphorylation of the receptor and activa-
tion of signal transducer and activator of tran-
scription (STAT)3 molecules. Activated STAT3
forms dimers, which translocate to the nucleus
and activate target genes including suppressor of
cytokine signaling (SOCS)3. Increased STAT3-
mediated SOCS3 expression leads to the com-
bined feedback inhibition of leptin and insulin
signaling. Phosphorylated JAK2 also directly ac-
tivates the IRS/PI3 kinase signaling pathway,
initiating downstream signals such as activation of
serine/threonine kinases downstream of PIP3.
Moreover, leptin activates the MAPK pathway by
inducing tyrosine phosphorylation of Shc and its
association with Grb2. In POMC cells, insulin-
mediated activation of AKT leads to phosphory-
lation of FOXO1 and its exclusion from the
nucleus, thereby allowing for transcription of
Pomc. Pomc transcription is also increased by
binding of STAT3 to its promoter.
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2005). Of particular importance, all of the diverse biological
responses elicited by insulin stimulation display variant thresh-
olds for activation by insulin and therefore—already within phys-
iological ranges of circulating insulin concentrations—exhibit
differential physiological response patterns (Biddinger and
Kahn, 2006; Reaven, 2005). Moreover, the compensatory hyper-
insulinemia as present in patients with obesity or T2DM can still
initiate some insulin responses or even lead to overactivation of
others. Thus, a state of insulin resistance often reflects the simul-
taneous occurrence of cell type-specific attenuation or failure of
insulin signaling, maintained responses to insulin, and even
augmentation of insulin responses in cell types, which at physi-
ological insulin concentrations would otherwise not respond to
insulin but express functional IRs. Therefore, many of the meta-
bolic features of the obesity-associated Insulin Resistance
Syndrome may be secondary to the compensatory hyperinsuli-
nemia, and thus, the complex clinical outcome will largely differ
from a phenotype arising from a uniform reduction or ablation of
insulin signaling. This concept holds true not only for insulin
action and resistance in disease development but also for other
hormones, such as leptin.
In fact, similar to the manifestation of insulin resistance and
compensatory hyperinsulinemia, the majority of obese patients
and mouse models of dietary-induced obesity present with
elevated circulating leptin concentrations, indicative of leptin
resistance (Frederich et al., 1995; Friedman, 2009a, 2009b; Maf-
fei et al., 1995). In line with this, resistance to leptin’s effects but
also to insulin’s effects occurs not only in peripheral tissues but
also in the CNS, thereby triggering an adaptive increase of food
intake and body weight gain (Clegg et al., 2011; Konner et al.,
2009; Myers et al., 2010).
Selective Insulin Resistance in Peripheral Tissues
Failure of insulin to adequately suppress hepatic glucose
production clearly represents a hallmark of progression from
insulin resistance to overt diabetes mellitus. However, it was146 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.the liver, where selective hepatic insulin resistance was first
recognized, i.e., insulin fails to suppress glucose production
but continues to promote lipid synthesis (Biddinger et al.,
2008; Brown and Goldstein, 2008; Laplante and Sabatini,
2010). This paradox of selective hepatic insulin resistance in
the FOXO1 pathway but preserved insulin sensitivity in the
SREBP-1c pathway ultimately contributes to the classic triad
seen in humans with T2DM—hyperglycemia, hyperinsulinemia,
and hypertriglyceridemia. At least two mechanisms have been
suggested to contribute to uncoupling of insulin-dependent
regulation of gluconeogenesis and lipogenesis. Only recently,
a study by Li and colleagues could identify mTORC1 kinase as
an essential component in the insulin-regulated pathway for
hepatic lipogenesis but not gluconeogenesis, thereby identifying
one hepatic bifurcation point in the insulin signaling pathway (Li
et al., 2010) (Figure 1). Similarly, work by Stoffel and colleagues
revealed different thresholds and sensitivity for resistance de-
velopment for insulin-stimulated FOXA2 versus FOXO1 regula-
tion, providing another mechanism for dissociation of insulin’s
gluconeogenic versus lipogenic effects (Wolfrum et al., 2004)
(Figure 1).
In human obesity and T2DM, receptor binding and phosphor-
ylation of the IR and IRS1 are decreased in muscle (Cusi et al.,
2000). There is also a dramatic reduction in insulin stimulation
of the PI3 kinase pathway and glucose uptake (Cusi et al.,
2000; Goodyear et al., 1995; Kim et al., 1999). However, insulin
stimulation of the MAP kinase pathway is normal, indicating
that insulin resistance in humans differentially affects the PI3
kinase and MAP kinase signaling pathways (Cusi et al., 2000;
Kim et al., 1999). However, the clinical outcome of maintained
ERK activation in muscle in the presence of reduced insulin-
stimulated glucose uptake still has to be defined.
Cardiovascular pathologies in insulin-resistant and diabetic
patients are due to the acceleration of atherosclerosis, and clin-
ical studies indicate that insulin resistance at the vascular wall
could be important in the development of cardiovascular disease
in T2DM (Rask-Madsen and King, 2007). Insulin activates both
Figure 3. Proposed Model of Selective
Resistance to Insulin under Conditions of
Diet-Induced Obesity
In lean mice, insulin activates PI3 kinase signaling
in anorexigenic POMC neurons, which results in
neuronal silencing and is also required for Pomc
transcription. POMC-expressing neurons release
the POMC cleavage product a-melanocyte-stim-
ulating hormone, which acts on melanocortin 4
receptors (MC4R) on downstream target neurons
to reduce food intake, increase energy expendi-
ture, and regulate glucosemetabolism. Insulin also
activates PI3 kinase signaling in SF-1-expressing
neurons of the VMH and reduces their firing
frequency through activation of KATP channels.
Moreover, neurons located in the VMH provide
glutamatergic innervation of POMC neurons in
the ARC. Under obese conditions, ARC POMC
neurons become insulin resistant, thus further
promoting increased food intake and body weight
gain. However, in obese mice, increased insulin
concentrations promote strong PI3 kinase activa-
tion in SF-1 VMH neurons, resulting in cell-auton-
omous hyperpolarization. This, in turn, reduces
excitatory input onto ARC POMC neurons.
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cular endothelial cells, and it has been suggested that a
selective lack of insulin’s antiatherogenic actions on the vascula-
ture mediated by the activation of IRS/PI3K/AKT pathways with
preserved or even enhanced actions through the MAP kinase
signaling pathway could be a major cause for the development
and progression of atherogenesis and microvascular disease in
T2DM (Jiang et al., 1999; Rask-Madsen and King, 2007; Rask-
Madsen et al., 2010).
Finally, insulin action and resistance not only in vascular endo-
thelial cells but also in smooth muscle cells and macrophages
may contribute to the development of diabetes-associated car-
diovascular disease. While numerous studies indicate a role
for insulin resistance in macrophages to promote a proinflam-
matory, proatherogenic milieu (Han et al., 2006; Liang et al.,
2007; Senokuchi et al., 2008), we have demonstrated that com-
plete insulin resistance of macrophages due to myeloid lineage-
specific lack of IR confers protection, both from atherosclerosis
and diet-induced insulin resistance (Baumgartl et al., 2006;
Mauer et al., 2010). Development of pathway-selective insulin
resistance may explain these different experimental outcomes,
and it will be critical to assess the differential activation of
different insulin-evoked downstream signals in macrophages
during obesity development and during the onset of obesity-
associated insulin resistance.
Selective Insulin Resistance in the CNS
Notably, selective resistance to insulin signaling has been
demonstrated not only in peripheral tissues but also in the hypo-
thalamus of obese Zucker rats (Carvalheira et al., 2003). Insulin’s
central action in control of energy balance and glucose homeo-
stasis ismediated, at least in part, by PI3 kinase activation and its
product PIP3 (Konner et al., 2009; Niswender and Schwartz,
2003). In POMC cells, leptin- and insulin-stimulated PI3 kinase
activation is required for Pomc transcription and neuropep-
tide synthesis in a FOXO1-dependent manner (Belgardt et al.,
2008; Plum et al., 2009; Plum et al., 2006b) (Figure 2). Moreover,
studies in rodents have demonstrated a role for hypothalamicinsulin signaling in control of hepatic glucose production, which
also depends on insulin-stimulated activation of PI3 kinase
signaling and the regulation of KATP channels, specifically in
orexigenic AgRP neurons, as well as in the regulation of sympa-
thetic innervation of white adipose tissue (Gelling et al., 2006;
Konner et al., 2007; Obici et al., 2002a, 2002b; Plum et al., 2007).
In obese Zucker rats, insulin-stimulated PI3 kinase activation
in the hypothalamus is decreased compared to lean control
animals and, accordingly, intracerebroventricular insulin infusion
reduced food intake in lean rats to a greater extent than that
observed in obese rats. In contrast, insulin stimulated the phos-
phorylation of MAP kinase equally in lean and obese rats (Carval-
heira et al., 2003; Clegg et al., 2011). Thus, selective impairment
of insulin-evoked PI3 kinase signaling in the ARC—including
POMC and AgRP neurons—may contribute to the development
of hyperphagia and impairment of glucose metabolism upon
obesity development.
On the other hand, we could only recently demonstrate
that insulin activates PI3 kinase signaling in steroidogenic factor
1 (SF-1)-expressing neurons of the VMH and reduces firing
frequency in these cells through activation of KATP channels.
Interestingly, only under high-fat-diet conditions is insulin sig-
naling increased in SF-1-expressing neurons of the VMH, while
other cell types, i.e., POMC neurons in the ARC, become insulin
resistant (Klockener et al., 2011; Mayer and Belsham, 2010b;
Schubert et al., 2004) (Figure 3). Neurons located in the VMH
provide glutamatergic innervation of anorexigenic POMC neu-
rons in the ARC (Sternson et al., 2005), and electrophysiological
analysis revealed that exposure to high-fat diet impairs their
neuronal activity and subsequently that of their POMC target
neurons (Klockener et al., 2011) (Figure 3). Consistently, abroga-
tion of IR signaling from SF-1 VMH neurons restored activity of
anorexigenic POMC neurons under high-fat-diet conditions.
Importantly, SF-1 IR knockout mice with attenuated diet-
induced, insulin-dependent silencing of key anorexigenic VMH
neurons were protected from diet-induced weight gain, adi-
posity, and impaired glucose tolerance under high-fat feeding
(Klockener et al., 2011).Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc. 147
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ment of insulin resistance in the ARC of the hypothalamus and
overactivation of insulin signaling in the VMHupon obesity devel-
opment, with both effects synergizing in the manifestation of
obesity and obesity-associated deterioration of glucose metab-
olism (Figure 3).
Selective Insulin Resistance in the CNS in Disease
versus Physiological Insulin Action in the CNS
Over the last decade, the physiological role of insulin action in
the CNS has been subject to intense debate. While numerous
studies in rodents have supported a critical role for insulin action
in the CNS in control of peripheral glucose metabolism (see
above), studies in humans and in large mammals, such as the
dog, indicated that direct hepatic effects of insulin are dominant
in the suppression of the net hepatic glucose output (Edgerton
et al., 2006; Levin and Sherwin, 2011; Perseghin et al., 1997;
Ramnanan et al., 2011). Together, these results raise the ques-
tion about the physiological relevance of insulin action in the
brain on hepatic glucose metabolism.
In fact, the recognition that insulin when applied at pharmaco-
logical concentrations to the CNSmay exert partly counteracting
effects in control of feeding and glucose homeostasis by acting
through distinct neuronal populations such as AgRP, POMC,
VMH, and dopaminergic midbrain neurons, as well as additional
yet unidentified sites, may indicate that the overall net effect of
CNS insulin action in control of feeding and glucose metabolism
in lean subjects is minor. This notion is further supported by the
relatively mild phenotype of mice lacking the IR throughout the
CNS compared to mice lacking the leptin receptor in the CNS
(Bruning et al., 2000; Cohen et al., 2001). However, we propose
that simultaneous development of insulin resistance in the ARC
in the presence of maintained or increased insulin action in
distinct other neuronal populations upon high-fat feeding, such
as the VMH, may represent a critical determinant in the manifes-
tation of metabolic diseases upon obesity development. Thus,
defining the individual role of insulin action in distinct neurons
combined with the assessment of whether these sites gain,
retain, or lose insulin sensitivity upon obesity development will
ultimately allow delineation of the underlying basis of CNS-
dependent mechanisms of metabolic disorders.
Selective Leptin Resistance in the CNS
It is well documented that leptin resistance, particularly with
respect to its anorexigenic action via the ARC of the hypothal-
amus, contributes to obesity development (Myers et al., 2010).
However, selective resistance has also been described for lep-
tin (Correia and Rahmouni, 2006; Mark et al., 2002). Leptin’s
actions on the cardiovascular system include both pressor and
depressor effects. However, chronically increased leptin levels
have been shown to predominantly activate pressor effects
(Shek et al., 1998). Transgenic mice overexpressing leptin (trans-
genic skinny mice), whose elevated plasma leptin levels are
comparable to those seen in obese subjects, exhibit elevated
systolic blood pressure and urinary catecholamine excretion (Ai-
zawa-Abe et al., 2000). In contrast, leptin-deficient ob/ob mice
exhibit a significantly lower arterial pressure compared to lean
control mice, despite body weights being nearly twice as high
as in lean control animals (Mark et al., 1999). On the other148 Cell Metabolism 16, August 8, 2012 ª2012 Elsevier Inc.hand, mean arterial pressure is significantly higher in agouti
yellow obese mice, which ubiquitously overexpress the agouti
protein, a MC4R antagonist, and present with hyperleptinemia
and resistance to the anorexigenic effects of leptin but preserva-
tion of its sympathoexcitatory actions (Correia et al., 2002;
Mark et al., 1999; Rahmouni et al., 2002, 2005). Taken together,
these results may explain how hyperleptinemia, as present in
obese states, can contribute to the development of hyperten-
sion with simultaneous resistance to the metabolic actions of
leptin.
Molecular Basis of Selective Insulin and Leptin
Resistance
The underlying molecular mechanism(s) of insulin resistance is
only partially understood and heterogeneous in nature. The full
clinical manifestation of insulin and leptin resistance is limited
to rare genetic syndromes of inactivating mutations of the
IR in patients suffering from Donohue or Rabson-Mendenhall
syndromes or functional null mutations of the leptin receptor
gene (Farooqi and O’Rahilly, 2009; Semple et al., 2011). In fact,
the phenotypes resulting from these rare genetic syndromes
differ largely from the symptoms arising from selective resis-
tance as observed in the majority of subjects considered insulin
or leptin resistant. Here, insulin resistance has been demon-
strated to result from mutations or polymorphisms in down-
stream signaling molecules, such as IRS proteins, PI3 kinase,
or AKT, which naturally affect only distinct biological responses
of insulin action (for review, see Semple et al., 2011) (Figure 1).
In addition, variants in IRS proteins in turn can also affect signal
transduction of distinct downstream effectors, such as the
diabetes-predisposing variant Gly972-Arg of IRS1, which only
impairs insulin-evoked PI3 kinase activation, but not MAPK acti-
vation (Almind et al., 1996).
Similarly, obesity-associated posttranslational modifications,
such as JNK-, MAPK-, or p70 S6-kinase-dependent serine
phosphorylation of IRS molecules, besides attenuating the IR-
IRS interaction, only result in cell type- and pathway-specific
inhibition of insulin signaling dependent on the expression of
these effector kinases and their upstream activators. This is
highlighted by the profound effect of JNK-dependent inhibition
of insulin action in the CNS but its relatively minor contribution
to the development of obesity-associated insulin resistance in
skeletal muscle and liver (Belgardt et al., 2010a; Belgardt et al.,
2010b; Sabio et al., 2010; Tanti and Jager, 2009) (Figure 1).
Ultimately, altered posttranscriptional gene silencing via dys-
regulated microRNA expression as a more recently defined
mechanism of insulin resistance is clearly predicted to cause
both cell type- and pathway-selective resistance, due to the
cell type-specific expression of both microRNAs and their
targets, and due to themolecular mechanisms of how alteredmi-
croRNA targets affect insulin signaling (El Ouaamari et al., 2008;
Jordan et al., 2011; Krutzfeldt and Stoffel, 2006; Trajkovski et al.,
2011) (Figure 1).
Collectively, the molecular nature of the most prevalent
causes of insulin resistance indicates that selective hormone
resistance represents the rule rather than exception in the mani-
festation of insulin and leptin resistance associated with obesity,
and that resistance is predicted to either differentially affect
specific branches of insulin action and/or different cell types.
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the IRS/PI3 kinase/AKT/mTOR pathway but preserved signaling
through theMAP kinase signaling pathway may contribute to the
diverse clinical outcomes associated with insulin resistance
(Carvalheira et al., 2003; Cusi et al., 2000; Jiang et al., 1999;
Kim et al., 1999; Li et al., 2010). However, besides their indepen-
dent signaling, the Ras-ERK and PI3 kinase-mTOR pathway
crosstalk extensively and regulate each other both positively
and negatively (for review, see Mendoza et al., 2011). Thus,
crosstalk between the two pathways and the resultant coregula-
tion of downstream function clearly complicates interpretation of
studies, suggesting a strict bifurcation of these pathways in
insulin-resistant states.
In addition to the complex molecular basis of selective resis-
tance in peripheral tissues, the unique structure of the CNS
with its heterogeneous nature of distinct neuronal and nonneuro-
nal cell types and their differential accessibility to peripheral
signals offers additional mechanisms for the development of
selective hormone resistance in the brain. Consistent with selec-
tive leptin resistance in different hypothalamic nuclei, diet-
induced obese mice exhibited a selective reduction of leptin-
stimulated STAT3 phosphorylation in the ARC, concomitant
with increased expression of suppressor of cytokine signaling
3 (SOCS3), an inhibitor of leptin and insulin signaling specifically
in the ARC (Kievit et al., 2006; Mori et al., 2004; Munzberg et al.,
2004) (Figure 2). In line with this observation, leptin action in the
DMH increases sympathetic outflow to brown adipose tissue,
thereby inducing thermogenesis, which is retained in mice on
a high-calorie diet (Enriori et al., 2011). While localized increases
of SOCS3 expression may explain the occurrence of selective
insulin and leptin resistance, the major question about the
underlying molecular basis for this phenomenon still remains
largely unexplored. Here, differentially regulated leptin and in-
sulin sensitivity may result from differences in accessibility of
both hormones to neurons in different brain areas. Consistently,
POMC and AgRP neurons of the ARC are located directly next
to the median eminence, a circumventricular organ with a
highly permeable blood brain barrier (Mullier et al., 2010), and
thus POMC and AgRP neurons may sense elevated circulating
insulin/leptin concentrations, which could lead to receptor de-
sensitization (Mayer and Belsham, 2010a). Furthermore, fatty
acids can cause neuronal leptin and insulin resistance in the
ARC (Kleinridders et al., 2009; Konner and Bruning, 2011; Posey
et al., 2009). Also here, differential concentrations of fatty acids in
the ARC and even neighboring nuclei, such as the VMH, may
direct cell type-specific hormone resistance. Finally, obesity-
induced inflammation and particularly glia cell activation repre-
sent critical mediators in the development of leptin and insulin
resistance (Thaler et al., 2010). Therefore, future studies will
have to focus on the region-specific activation of these path-
ways, and, ultimately, on the mechanisms of regional inflamma-
tory responses in obesity.
Conclusions
Extensive elegant studies have provided novel insights into how
insulin/leptin resistance can develop in some pathways while
sensitivity ismaintained in others, and furthermore, these studies
also defined the differential contributions of distinct tissues/brain
regions to the development of metabolic disorders. Differentiallevels of resistance in tissues or even neuronal circuits, as well
as in intracellular signaling pathways targeted by insulin/leptin,
may contribute to the development of metabolic diseases.
Future studies of the complex network of insulin and also leptin
signaling will hopefully increase our knowledge on molecular
mechanisms underlying selective hormonal resistance. Taken
together, the concept of differential hormone sensitivity and
resistance, both in peripheral tissues and the CNS, represents
a key step in disease development, and thus points to the neces-
sity to develop cell type-specific hormone sensitizers in the treat-
ment of metabolic diseases.
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